Home › Companies › Amylyx Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Amylyx Pharmaceuticals, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 4 items on Amylyx Pharmaceuticals, Inc.’s Form 8-K, filed June 4, 2026: 2 approved · 2 passed (calculated).
Notable dissent: 1 director (15.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 3.3%, as of September 30, 2026)
Explore Amylyx Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Amylyx Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: George Mclean Milne Jr., Ph.D. | 76,937,972 | -- | -- | 14,108,630 | 11,029,810 | 85% | Passed (calculated) | — |
| Elect Director: Paul Fonteyne | 86,275,670 | -- | -- | 4,770,932 | 11,029,810 | 95% | Passed (calculated) | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 102,036,295 | 34,484 | 5,633 | -- | 0 | 99.9% | Approved | — |
| 3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers | 77,534,824 | 13,490,653 | 21,125 | -- | 11,029,810 | 85% | Approved | — |
Source: Amylyx Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
217 asset managers disclosed a vote on at least one Amylyx Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: George Mclean Milne Jr., Ph.D.
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: George Mclean Milne Jr., Ph.D.”): 76,937,972 for, 14,108,630 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 31,262,472 for, 2,757,116 withheld, 28 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,590,784 | 0 | 0 | 0 | For |
| Vanguard | 5,028,218 | 0 | 28 | 10,908 | For |
| BlackRock | 4,450,090 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 1,364,236 | Withhold |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 396,719 | 0 | 0 | 389 | For |
| Prudential/PGIM | 373,490 | 0 | 0 | 2,560 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 282,418 | Withhold |
| Equitable | 179,733 | 0 | 0 | 49,500 | Mixed |
| First Trust | 0 | 0 | 0 | 228,569 | Withhold |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 189,605 | Withhold |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 136,216 | Withhold |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 89,983 | Withhold |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 59,414 | Withhold |
| Northern Trust | 0 | 0 | 0 | 58,983 | Withhold |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,098 | 0 | 0 | 47,259 | Withhold |
| Brighthouse | 14,699 | 0 | 0 | 29,276 | Mixed |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Paul Fonteyne
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Paul Fonteyne”): 86,275,670 for, 4,770,932 withheld, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 31,990,479 for, 2,029,126 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,567,874 | 0 | 0 | 22,910 | For |
| Vanguard | 5,031,831 | 0 | 11 | 7,312 | For |
| BlackRock | 4,104,535 | 0 | 0 | 345,555 | Mixed |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 1,364,236 | Withhold |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 396,995 | 0 | 0 | 113 | For |
| Prudential/PGIM | 373,490 | 0 | 0 | 2,560 | For |
| DRIEHAUS MUTUAL FUNDS | 282,418 | 0 | 0 | 0 | For |
| Equitable | 229,233 | 0 | 0 | 0 | For |
| First Trust | 228,569 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 189,605 | Withhold |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 136,216 | 0 | 0 | 0 | For |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 89,983 | 0 | 0 | 0 | For |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 59,414 | 0 | 0 | 0 | For |
| Northern Trust | 58,983 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 49,357 | 0 | 0 | 0 | For |
| Brighthouse | 43,975 | 0 | 0 | 0 | For |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
85% Approved · of votes cast
Prior year: 57.9% for (June 5, 2025 meeting) ▲ 27.3 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“3. Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers”): 77,534,824 for, 13,490,653 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers .”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,590,784 | 0 | 0 | 0 | For |
| Vanguard | 5,039,126 | 28 | 0 | 0 | For |
| BlackRock | 4,450,090 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 1,364,236 | 0 | 0 | Against |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 396,832 | 276 | 0 | 0 | For |
| Prudential/PGIM | 373,490 | 2,560 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 282,418 | 0 | 0 | Against |
| Equitable | 179,733 | 49,500 | 0 | 0 | Mixed |
| First Trust | 0 | 228,569 | 0 | 0 | Against |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 189,605 | 0 | 0 | Against |
| TIAA | 0 | 175,343 | 0 | 0 | Against |
| RBB FUND, INC. | 0 | 136,216 | 0 | 0 | Against |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 89,983 | 0 | 0 | Against |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 59,414 | 0 | 0 | Against |
| Northern Trust | 58,983 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 2,098 | 47,259 | 0 | 0 | Against |
| Brighthouse | 14,699 | 29,276 | 0 | 0 | Mixed |
| Global X | 42,973 | 0 | 0 | 0 | For |
Fund voting reports, all 59 managers: 31,158,948 for, 2,856,718 against, 3,152 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,531,669 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 5,695,994 | 0 | 0 | 0 | For |
| Commodore Capital LP | 5,650,000 | 0 | 0 | 0 | For |
| Janus Henderson | 4,609,500 | 0 | 0 | 0 | For |
| Saturn V Capital Management LP | 4,259,868 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 3,146,028 | 0 | 0 | Against |
| GREAT POINT PARTNERS LLC | 3,127,204 | 0 | 0 | 0 | For |
| BlackRock | 3,083,597 | 11,736 | 0 | 0 | For |
| First Light Asset Management, LLC | 3,092,866 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 2,600,516 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 0 | 2,536,555 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 2,207,533 | 0 | 0 | 0 | For |
| State Street | 1,981,073 | 25,924 | 0 | 0 | For |
| 683 Capital Management, LLC | 1,497,683 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,197,511 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,084,738 | 0 | 0 | 0 | For |
| Woodline Partners LP | 845,800 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 841,275 | 0 | 0 | 0 | For |
| Vanguard | 702,125 | 16,223 | 0 | 0 | For |
| Charles Schwab | 717,227 | 0 | 0 | 0 | For |
| JUPITER ASSET MANAGEMENT LTD | 0 | 571,559 | 0 | 0 | Against |
| Nantahala Capital Management, LLC | 535,684 | 0 | 0 | 0 | For |
| Northern Trust | 506,050 | 24,098 | 0 | 0 | For |
| Rock Springs Capital Management LP | 0 | 499,764 | 0 | 0 | Against |
| Federated Hermes | 354,606 | 0 | 0 | 0 | For |
Institutional-manager reports, all 175 managers: 60,760,162 for, 11,745,062 against, 164 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 5, 2025 meeting) unchanged
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Amylyx Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 102,036,295 for, 34,484 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 34,016,464 for, 3,152 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,590,784 | 0 | 0 | 0 | For |
| Vanguard | 5,039,154 | 0 | 0 | 0 | For |
| BlackRock | 4,450,090 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,512,444 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,364,236 | 0 | 0 | 0 | For |
| Charles Schwab | 714,213 | 0 | 0 | 0 | For |
| State Street | 397,108 | 0 | 0 | 0 | For |
| Prudential/PGIM | 376,050 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 282,418 | 0 | 0 | 0 | For |
| Equitable | 229,233 | 0 | 0 | 0 | For |
| First Trust | 228,569 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 219,001 | 0 | 0 | 0 | For |
| Dimensional | 189,605 | 0 | 0 | 0 | For |
| TIAA | 175,343 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 136,216 | 0 | 0 | 0 | For |
| Federated Hermes | 127,981 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 89,983 | 0 | 0 | 0 | For |
| JPMorgan | 85,210 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 59,414 | 0 | 0 | 0 | For |
| Northern Trust | 58,983 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,400 | 0 | 0 | 0 | For |
| Goldman Sachs | 53,999 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 49,357 | 0 | 0 | 0 | For |
| Brighthouse | 43,975 | 0 | 0 | 0 | For |
| Global X | 42,973 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 111,026,477 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 15.84% |
| 2 | Vanguard | 4.54% |
| 3 | BlackRock | 4.01% |
| 4 | MUTUAL FUND SERIES TRUST | 1.36% |
| 5 | FRANKLIN STRATEGIC SERIES | 1.23% |
| 6 | Charles Schwab | 0.64% |
| 7 | State Street | 0.36% |
| 8 | Prudential/PGIM | 0.34% |
| 9 | DRIEHAUS MUTUAL FUNDS | 0.25% |
| 10 | Equitable | 0.21% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.89% |
| 2 | PERCEPTIVE ADVISORS LLC | 5.13% |
| 3 | Commodore Capital LP | 5.09% |
| 4 | Janus Henderson | 4.15% |
| 5 | Saturn V Capital Management LP | 3.84% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.83% |
| 7 | GREAT POINT PARTNERS LLC | 2.82% |
| 8 | BlackRock | 2.79% |
| 9 | First Light Asset Management, LLC | 2.79% |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.34% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 16,630,541 | 14.98% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 8,828,836 | 7.95% | Form 13F, quarter ended March 31, 2026 |
| TCG Crossover GP II, LLC | 6,243,812 | 5.62% | Schedule 13G, filed February 17, 2026 |
| Vanguard Group | 5,804,912 | 5.23% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 2,625,991 | 2.37% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,363,161 | 2.13% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 2,359,824 | 2.13% | Form 13F, quarter ended March 31, 2026 |
| Franklin Templeton | 2,261,569 | 2.04% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 2,210,932 | 1.99% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 903,192 | 0.81% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 111,026,477 shares outstanding, as reported by Amylyx Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Amylyx Pharmaceuticals, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 217 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,061 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — Amylyx Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 85% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Amylyx Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Amylyx Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Amylyx Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Amylyx Pharmaceuticals (AMLX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amylyx-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.